Evidence map›Paper›PMID 24686251›Full record

ArticlePloS one2014

Large genomic rearrangements of BRCA1 and BRCA2 among patients referred for genetic analysis in Galicia (NW Spain): delimitation and mechanism of three novel BRCA1 rearrangements.

Laura Fachal, Ana Blanco, Marta Santamariña, Angel Carracedo, Ana Vega

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. BRACNAC: AInternational journal of molecular sciences · 2023
    Article
  5. Review
  6. Article
  7. Review
  8. Complex Characterization of Germline Large Genomic Rearrangements of theInternational journal of molecular sciences · 2020
    Article
  9. Article
  10. Article
  11. Review
  12. New challenges for BRCA testing: a view from the diagnostic laboratory.European journal of human genetics : EJHG · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Laura FachalFundación Pública Galega de Medicina Xenómica-SERGAS. Grupo de Medicina Xenómica, CIBERER, IDIS, Santiago de Compostela, Spain.
Ana BlancoFundación Pública Galega de Medicina Xenómica-SERGAS. Grupo de Medicina Xenómica, CIBERER, IDIS, Santiago de Compostela, Spain.
Marta SantamariñaGrupo de Medicina Xenómica -USC, University of Santiago de Compostela, CIBERER, IDIS, Santiago de Compostela, Spain.
Angel CarracedoFundación Pública Galega de Medicina Xenómica-SERGAS. Grupo de Medicina Xenómica, CIBERER, IDIS, Santiago de Compostela, Spain.
Ana VegaFundación Pública Galega de Medicina Xenómica-SERGAS. Grupo de Medicina Xenómica, CIBERER, IDIS, Santiago de Compostela, Spain.
Fundación Pública Galega de Medicina Xenómica · ESServicio Gallego de Salud · ESUniversidade de Santiago de Compostela · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the Iberian Peninsula, which includes mainly Spain and Portugal, large genomic rearrangements (LGRs) of BRCA1 and BRCA2 have respectively been found in up to 2.33% and 8.4% of families with hereditary breast and/or ovarian cancer (HBOC) that lack point mutations and small indels. In Galicia (Northwest Spain), the spectrum and frequency of BRCA1/BRCA2 point mutations differs from the rest of the Iberian populations. However, to date there are no Galician frequency reports of BRCA1/BRCA2 LGRs. Here we used multiplex ligation-dependent probe amplification (MLPA) to screen 651 Galician index cases (out of the 830 individuals referred for genetic analysis) without point mutations or small indels. We identified three different BRCA1 LGRs in four families. Two of them have been previously classified as pathogenic LGRs: the complete deletion of BRCA1 (identified in two unrelated families) and the deletion of exons 1 to 13. We also identified the duplication of exons 1 and 2 that is a LGR with unknown pathogenicity. Determination of the breakpoints of the BRCA1 LGRs using CNV/SNP arrays and sequencing identified them as NG_005905.2:g.70536_180359del, NG_005905.2:g.90012_97270dup, and NC_000017.10:g.41230935_41399840delinsAluSx1, respectively; previous observations of BRCA1 exon1-24del, exon1-2dup, and exon1-13del LGRs have not characterized them in such detail. All the BRCA1 LGRs arose from unequal homologous recombination events involving Alu elements. We also detected, by sequencing, one BRCA2 LGR, the Portuguese founder mutation c.156_157insAluYa5. The low frequency of BRCA1 LGRs within BRCA1 mutation carriers in Galicia (2.34%, 95% CI: 0.61-7.22) seems to differ from the Spanish population (9.93%, 95% CI: 6.76-14.27, P-value = 0.013) and from the rest of the Iberian population (9.76%, 95% CI: 6.69-13.94, P-value = 0.014).

Indexed as

AdultBase SequenceBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsExonsFemaleGene RearrangementGenetic TestingHumansMaleMiddle AgedMolecular Sequence DataOvarian NeoplasmsPedigreePoint MutationBRCA1 ProteinBRCA2 Protein

Identifiers

PMID24686251
PMCPMC3970959
OpenAlexW2099472787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.